drugset

drugset / Trial / NCT03724409

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

NCT03724409 ↗

Phase 0 Terminated 3 enrolled Sandeep Laroia Holden Comprehensive Cancer Center · collab National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a safety study to determine the phase 1 starting dose of \[90\]Yttrium-DOTATOC when it is administered intravenously for patients with neuroendocrine tumors that have spread to the liver.

Timeline

Start: 2018-10-11
Primary completion: 2021-03-21
Completion: 2023-05-23

Publications

Background Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P; NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015 Jan;17(1):29-37. doi: 10.1111/hpb.12326. Epub 2014 Sep 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	90Y-DOTATOC	Peptide	2960 mbq	Other
Subject	90Y-DOTATOC	Peptide	3330 mbq	Other
Subject	90Y-DOTATOC	Peptide	3700 mbq	Other
Subject	90Y-DOTATOC	Peptide	4170 mbq	Other
Subject	90Y-DOTATOC	Peptide	4440 mbq	Other
Subject	90Y-DOTATOC	Peptide	5180 mbq	Other

Indications